1. Home
  2. MXCT vs QMLS Comparison

MXCT vs QMLS Comparison

Compare MXCT & QMLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Logo QumulusAI Inc. Common Stock

QMLS

QumulusAI Inc. Common Stock

HOLD

Current Price

$1.88

Market Cap

127.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXCT
QMLS
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
127.1M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
MXCT
QMLS
Price
$1.38
$1.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$4.11
★ $10.33
AVG Volume (30 Days)
★ 1.4M
236.4K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $33,026,000.00
N/A
Revenue This Year
$4.77
$371.05
Revenue Next Year
$10.06
$427.05
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$2.08
52 Week High
$1.80
$14.82

Technical Indicators

Market Signals
Indicator
MXCT
QMLS
Relative Strength Index (RSI) 55.07 28.98
Support Level $1.02 N/A
Resistance Level $1.54 $3.91
Average True Range (ATR) 0.14 0.49
MACD -0.01 -0.02
Stochastic Oscillator 70.41 3.22

Price Performance

Historical Comparison
MXCT
QMLS

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About QMLS QumulusAI Inc. Common Stock

QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.

Share on Social Networks: